AMS is the developer of BSL-177, the world’s first compact system that treats radioactive urine from nuclear medicine patients, protecting staff, patients, and the environment from contamination. Learn more about the Tokyo-based organization in this installment of our Let’s Interview Series.
Venture Valuation (VV) interviewed SUGAWARA Yuichiro, Founder, President and CEO.
Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?